Trastuzumab is approved for the treatment of breast, gastric and gastroesophageal junction cancer by the US Federal Drugs Administration (FDA), and there are mounting anecdotal reports of responses to HER2-targeted agents in patients with NSCLC [29–33] and cancer of the salivary duct [34–38]. The gene discussed is ERBB2; the disease is cancer.